Literature DB >> 1320652

Varicella vaccine: the American experience.

A A Gershon1, P LaRussa, I Hardy, S Steinberg, S Silverstein.   

Abstract

Live attenuated varicella vaccine is safe and effective in preventing chickenpox. The best immune responses occur in healthy children. Leukemic children have a 50% incidence of mild-to-moderate adverse effects but have a high degree of protection once immune reactions to varicella-zoster virus (VZV) have developed. Adult vaccinees have a lower degree of protection (70%) than children. Vaccinees who develop breakthrough varicella usually have a modified infection. Another significant advantage of vaccination is that in leukemic children it leads to a lower incidence of zoster than after natural chickenpox. It is possible to differentiate between vaccine-type and wild-type VZV using a combination of polymerase chain reaction and restriction endonuclease digestion. A new assay for antibodies to VZV measured by latex agglutination reveals that 8-10 years after vaccination antibodies are detectable in greater than 90% of leukemic children who have not had breakthrough varicella.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320652     DOI: 10.1093/infdis/166.supplement_1.s63

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Peril of the pox. Are primary care providers aware of varicella vaccination guidelines?

Authors:  Darshini Persaude; Lorna Teape-Humphrey; Raquel Adelstein; Sharon Domb; Liisa Jaakkimainen
Journal:  Can Fam Physician       Date:  2002-02       Impact factor: 3.275

Review 2.  Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients.

Authors:  Martina Prelog; Jörn Schönlaub; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-11-15       Impact factor: 3.714

3.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

4.  Attenuated varicella virus vaccine in children with renal transplants.

Authors:  I Zamora; J M Simon; M E Da Silva; A I Piqueras
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 5.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

6.  Varicella-zoster virus infection of human neural cells in vivo.

Authors:  Armin Baiker; Klaus Fabel; Antonio Cozzio; Leigh Zerboni; Konstanze Fabel; Marvin Sommer; Nobuko Uchida; Dongping He; Irving Weissman; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

7.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 8.  Neurovirulence of varicella and the live attenuated varicella vaccine virus.

Authors:  Corey Horien; Charles Grose
Journal:  Semin Pediatr Neurol       Date:  2012-09       Impact factor: 1.636

9.  Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro.

Authors:  J I Cohen; K E Seidel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

10.  Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro.

Authors:  T C Heineman; J I Cohen
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.